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Controlling inﬂammation: a fat chance?
 
Roderick J. Flower and Mauro Perretti
 
The inflammatory response protects the body against infection and injury but 
can itself become deregulated with deleterious consequences to the host. It is 
now clear that several endogenous biochemical pathways activated during 
defense reactions can counterregulate inflammation. New experimental 
evidence adds resolvin E1 to this group of endogenous inhibitors and provides 
further rationale for the beneficial effects of dietary supplementation with 
fish oils. It also highlights an unexpected twist in the pharmacology of aspirin.
 
Polyunsaturated fatty acids and diet
 
The discovery in the 1930s by George
and Mildred Burr (1) that certain poly-
unsaturated fatty acids were “essential”
to the health of mammals begged the
question of why they were so crucial.
Initially it was thought that their im-
portance lay in their unique viscotropic
effect on biological membranes, but the
further discovery in the 1960s that all
essential fatty acids were also substrates
for prostaglandin synthesis by the cy-
clooxygenase enzymes (2) lead to the
realization that, in addition to being
important structural components of the
cell, these lipids were the precursors of
potent hormones with widespread effects
on the cardiovascular and immune sys-
tems. The subsequent demonstration that
other mediators such as the leukotrienes
(derived from the 5
 
 
 
-lipoxygenase [3])
and, more recently, that the endocanna-
binoids (4) could also be derived from
these same precursors, further high-
lighted this unusual property of these
versatile lipids.
The essential fatty acids, which in-
clude arachidonic and eicosapentaenoic
acids, cannot be synthesized by mammals
de novo but must be supplied in the
diet either as the native lipids or as im-
mediate precursors, such as linoleic or
 
 
 
–linolenic acids, which are then con-
verted by chain elongation and desatu-
ration reactions into the required end
product. Arachidonic acid is a 20-carbon
fatty acid with 4 unsaturated double
bonds located at positions (all cis) 5, 8,
11, and 14 in the hydrocarbon chain
(counting from C1, the COOH termi-
nal). Arachidonic acid belongs to a group
of fatty acids sometimes known as 
 
 
 
-6
fatty acids, so called because of the lo-
cation of the final double bond from
C20. Since the main source of essential
fatty acids is foodstuffs, it follows that
the actual composition of essential fatty
acids in the body reflects to a large extent
the nature of the diet. Although arachi-
donic acid is abundant in the tissues of
many land-dwelling animals, fish and
marine mammals have a preponderance
of the closely related eicosapentaenoic
acid with five double bonds arranged at
positions 5, 8, 11, 14, and 17 (thus be-
longing to the 
 
 
 
-3 group). It has been
suggested (5) that mankind evolved on
a diet where the ratio of 
 
 
 
-6:
 
 
 
-3 fatty
acids was 
 
 
 
1:1, as opposed to the pre-
vailing ratio (at least in Western societies)
of 10–20:1. The implication is that the
onset and progress of many inflamma-
tory and other diseases may be exacer-
bated by this shift in dietary habits.
When oxidized by the cyclooxy-
genase enzyme systems, arachidonic
acid gives rise to the “2” series of pros-
taglandins such as PGE
 
2
 
, PGF
 
2
 
 
 
, and so
on, because of the loss of two unsatur-
ated bonds during the cyclooxygenase
reaction, and to the “4” series of leu-
kotrienes, such as LTB
 
4
 
. However the
properties of eicosapentaenoic acid in
this respect are quite different. To begin
with, eicosapentaenoic acid is not a par-
ticularly good substrate for the cyclooxy-
genase and actually competitively in-
hibits arachidonic acid oxidation in vitro
(6). PGE
 
3
 
 is produced from eicosapen-
taenoic acid by the cyclooxygenase but
is less active than PGE
 
2
 
 in producing
various biological effects relevant to in-
flammation (7). Eicosapentaenoic acid
is, however, a good substrate for li-
poxygenases, although LTB
 
5
 
 is 
 
 
 
30
times less active as an activator of neu-
trophils than LTB
 
4
 
 (8).
It had been deduced from epidemi-
ological and dietary studies of different
populations, such as the Greenland Eski-
mos (9), that a preponderance of fish in
the diet was generally associated with a
reduced incidence of inflammatory and
cardiovascular disease. Over the years, a
great number of studies have tested ex-
tracts of fish oil (which usually contain
a mixture of eicosapentaenoic acid to-
gether with other associated fatty acids
such as docosahexaenoic acid) as dietary
supplements, finding a beneficial effect
in a wide range of human inflammatory
conditions including rheumatoid arthritis
(10), cystic fibrosis (11), ulcerative colitis
(12), UV-induced skin damage (13),
septic shock (14), and asthma (15). Pa-
tients fed diets rich in eicosapentaenoic
acid have been shown to express fewer
inflammatory biomarkers (16), reduced
leukocyte activation and mobility (17),
and diminished production of prosta-
glandins and platelet-activating factor
ex vivo (14); similar effects have been
seen in many animal studies (18).
Eicosapentaenoic acid is, therefore, one
of the few “nutriceuticals” for which
there is compelling evidence of effi-
cacy, although the optimum dosage has
perhaps yet to be established.
 
Explaining the beneficial effects
 
The most widely accepted explanation
for the efficacy of eicosapentaenoic acid
was that increasing proportions of this
fatty acid incorporated into the cellular
phospholipid pool reduces the net frac-
tion of arachidonic acid released during
cell activation, leading to less arachi-
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donic acid oxidation overall and to the
production of a different panel of lipid
mediators. In man, a dose-related re-
placement of membrane fatty acids oc-
curs after ingestion of up to 1.6 g eicos-
apentaenoic acid/day (10), an effect
more pronounced when the amount of
arachidonic acid in the diet was con-
comitantly restricted (19). In animal
studies, feeding increased amounts of
eicosapentaenoic acid reduced the
amount of arachidonic acid present in
cells, and led to a reduction in the pro-
duction of prostaglandins such as PGE
 
2
 
in experimental lesions (18).
But other explanations for the effi-
cacy of eicosapentaenoic acid have also
been suggested. It has been postu-
lated, for example, that 15-lipoxygen-
ase products of eicosapentaenoic acid
themselves can interfere with the acti-
vation of the transcription factor NF-
 
 
 
B and thus prevent the activation of
inflammatory genes (20), or that eicos-
apentaenoic acid blocks the terminal
stages of arachidonic acid synthesis
from its precursors in vivo (21). But in
this issue (page 713), Arita et al. have
come up with another fascinating
observation which relates directly to
the efficacy of eicosapentaenoic acid as
a potential antiinflammatory in man
and,  interestingly enough, implicates
another popular therapeutic agent, as-
pirin, in a unique joint antiinflamma-
tory mechanism (22).
The work described by Arita et al.
(22) follows earlier discoveries by this
team, lead by Charlie Serhan, of other
groups of potent lipid mediators de-
rived from arachidonic acid, including
the lipoxins, resolvins, docosatrienes,
and neuroprotectins (23). In this issue,
Arita et al. describe the generation,
by the aspirin-treated cyclooxygenase
(COX)-2, of a 15-epi product of eicos-
apentaenoic acid (5S, 12R, 18R-trihy-
droxy-6Z, 8E, 10E, 14Z, 16E-eicoasa-
pentaenoic acid) which is subsequently
transformed to resolvin E1, a com-
pound previously found by the group
to be present during the resolution
phase of murine inflammation (24). By
extending his observations into man,
Serhan’s group has now placed the
whole idea of antiinflammatory lipids
on a new and more relevant therapeu-
tic footing.
The mechanism described here is
an interesting one for several reasons.
In contrast to its action on COX-1, as-
pirin does not totally inhibit the oxida-
tion of arachidonic acid (or other poly-
unsaturated fatty acid substrates) by
COX-2 (25), and although the aspirin-
inhibited enzyme cannot produce pros-
taglandins it retains the ability to gener-
ate a monohydroxy fatty acid species.
The most likely source of the COX-2
in this instance is the endothelial cell.
In the presence of eicosapentaenoic
acid and when “inhibited” by aspirin,
COX-2 can release the 18R-hydroxy
eicosapentaenoic acid precursor of re-
solvin E1. However, this moiety can-
not be further metabolized by the
endothelial cell itself, and its transfor-
mation to resolvin E1 depends on the
presence of the 5-lipoxygenase enzyme
in adjacent leukocytes that are presum-
ably adherent to the vessel wall (Fig. 1).
The resolvin E1 product was measured
in bioactive concentrations in the
plasma of volunteers taking both eicos-
apentaenoic acid (1 g) and low dose as-
pirin (160 mg).
 
Versatility of G protein–
coupled receptors
 
The striking antiinflammatory activity
of lipoxin A
 
4
 
 (LXA
 
4
 
) as an inhibitor of
leukocyte activation, as earlier described
by Serhan’s group (26), was rather sur-
prisingly manifested through interaction
with a member of the formyl peptide
receptor (FPR) family termed ALXR
(or FPR-like 1). This finding was un-
expected, as this family of receptors,
which comprises at least three subtypes
in humans, is generally considered to be
a promoter rather than an inhibitor of
leukocyte chemotaxis and activation
(27). However, the recent notion that
another endogenous antiinflammatory
protein, annexin 1, also acts through
ALXR reinforces the concept that this
receptor may also have a protective an-
tiinflammatory function (28).
As in the case of LXA
 
4
 
, Serhan’s
group has found that resolvin E1 exerts
its antiinflammatory effects by acting
through a G protein–coupled receptor
to down-regulate NF-
 
 
 
B activation
(22). This receptor (subsequently re-
ferred to as ChemR23), which seems
fairly widely distributed in human tis-
sues, is related to ALXR and was origi-
Figure 1. Resolvin E1 and its receptor; a novel antiinflammatory circuit. Transcellular synthesis 
of resolvin E1 from diet-ingested eicosapentaenoic acid (EPA) occurs within the microcirculation by the 
concerted action of endothelial cell COX-2 and neutrophil 5-lipoxygenase (5-LO). After aspirin treatment, 
resolvin E1 synthesis occurs even in the absence of inflammation. Aspirin inactivates COX-2 but per-
mits continuing generation of the intermediate 18R-hydroxy-EPA which is converted to resolvin E1 
(or 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid) by the 5  lipoxygenase in 
adjacent neutrophils. This lipid can then act in a paracrine or autocrine fashion on a specific seven-
transmembrane G protein–coupled receptor, termed ChemR23, to bring about inhibitory effects on leu-
kocyte activation presumably with reduced synthesis and reduced release of proinflammatory media-
tors: the end point of resolvin E1–ChemR23 mediated effects is a reduced flux of blood-borne cells 
into the site of inflammation.
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nally described as a receptor for a che-
motactic peptide called chemerin. The
promiscuity of the FPR family of seven-
transmembrane G protein–coupled re-
ceptors may be gauged by the number
and diversity of the ligands they recog-
nize, which include lipids, peptides,
proteins, bile acids, and even enzymes.
It seems that Serhan’s group has uncov-
ered an additional example of a series of
lipids that exert their activities by bind-
ing to a receptor that might, under other
circumstances, actually promote leuko-
cyte chemotaxis (22). It is likely that
receptors such as FPR, ALXR, and
ChemR23 can assume ligand-specific
conformations,  hence transducing sig-
nals specific to each agonist. This con-
cept has been advanced for several G
protein–coupled receptors (29), includ-
ing those of the FPR family (30).
 
The lure of endogenous antiinflammatories
 
The notion that the inflammatory re-
sponse generates its own regulators in
tandem with the better known proin-
flammatory mediators such as prosta-
glandins and leukotrienes makes sense
from the cybernetic viewpoint as it is
easier to control a process with both
positive and negative regulatory inputs.
Indeed, several other instances of en-
dogenous regulators of the inflamma-
tory response (31) have been character-
ized recently (32), adding support to the
idea that this is a widely employed
mechanism. Clearly, disturbances in
such counterregulatory circuits could
lead to exacerbated inflammatory re-
sponses just as effectively (although per-
haps less obviously) than excessive acti-
vation of the proinflammatory cascades.
 
Aspirin: more than one mechanism?
 
This study also throws into sharp relief
yet another previously unsuspected ac-
tion of aspirin—its ability to facilitate
the generation of antiinflammatory
lipids from eicosapentaenoic acid and
arachidonic acid (33). This property,
which Serhan’s group has noted may be
shared by indomethacin and acetamino-
phen (24), can now be added to the cat-
alog of antiinflammatory effects of aspi-
rin which have recently been the focus
of other investigations (34). It is a sober-
ing thought that aspirin, the first and ar-
guably the simplest in chemical terms of
all the modern antiinflammatory drugs,
should have such complex and pro-
found effects.
 
Clinical horizons
 
So where does this leave us in terms of
practical therapeutics? It would seem
that the antiinflammatory effects of
eicosapentaenoic acid might be radi-
cally enhanced with low dose aspirin,
and a priority should now be a formal
clinical trial designed to test the addi-
tive action of these two agents in an in-
flammatory disease—perhaps rheuma-
toid arthritis—by monitoring plasma
resolvin E1 levels and disease outcome.
We also need to know whether re-
solvin E1 is found in vivo in the ab-
sence of aspirin treatment (and how)
and whether other nonsteroidal antiin-
flammatory drugs such as indometha-
cin also promote its synthesis. But we
should not overlook the cardiovascular
implications of this work. Aspirin itself
is, of course, used already in low doses
for the prophylactic treatment of pa-
tients at risk from myocardial infarction
and other cardiovascular pathologies,
and eicosapentaenoic acid has been
shown already to be beneficial in these
conditions as well. For example, the
data reported in the GISSI (Gruppo
Italiano per lo Studio della Soprav-
vivenza nell’Infarto miocardico) study
(35), quoted by the authors, demon-
strates a beneficial effect of eicosapen-
taenoic acid in patients at risk for myo-
cardial infarct, many of whom were
taking aspirin. In the light of the evi-
dence presented by Serhan’s group
(22), we should now also take a closer
look at the aspirin–eicosapentaenoic
acid interactions in the cardiovascular
arena. We need to discover any direct
effects resolvin E1 may have on platelet
function and to investigate whether
any beneficial effects that may be seen
in cardiovascular disease depend on the
antiinflammatory effects of this com-
pound or on other actions.
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